From the Department of Obstetrics and Gynecology, Clinic for Reproductive Endocrinology, University Hospital Zurich (R.K.D., I.B., R.S., B.L., B.I., M.R.).
Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland (R.K.D.).
Hypertension. 2020 Jan;75(1):109-118. doi: 10.1161/HYPERTENSIONAHA.119.13698. Epub 2019 Dec 2.
c-Kit+ progenitor smooth muscle cells (P-SMCs) can develop into SMCs that contribute to injury-induced neointimal thickening. Here, we investigated whether adenosine reduces P-SMC migration and proliferation and whether this contributes to adenosine's inhibitory actions on neointima formation. In human P-SMCs, 2-chloroadenosine (stable adenosine analogue) and BAY60-6583 (A agonist) inhibited P-SMC proliferation and migration. Likewise, increasing endogenous adenosine by blocking adenosine metabolism with erythro-9-(2-hydroxy-3-nonyl) adenine (inhibits adenosine deaminase) and 5-iodotubercidin (inhibits adenosine kinase) attenuated P-SMC proliferation and migration. Neither N-cyclopentyladenosine (A agonist), CGS21680 (A agonist), nor N-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (A agonist) affected P-SMC proliferation or migration. 2-Chloroadenosine increased cyclic AMP, reduced Akt phosphorylation (activates cyclin D expression), and reduced levels of cyclin D1 (promotes cell-cycle progression). Moreover, 2-chloroadenosine inhibited expression of Skp2 (promotes proteolysis of p27) and upregulated levels of p27 (negative cell-cycle regulator). A receptor knockdown prevented the effects of 2-chloroadenosine on cyclic AMP production and P-SMC proliferation and migration. Likewise, inhibition of adenylyl cyclase and protein kinase A rescued P-SMCs from the inhibitory effects of 2-chloroadenosine. The inhibitory effects of adenosine were similar in male and female P-SMCs. In vivo, peri-arterial (rat carotid artery) 2-chloroadenosine (20 μmol/L for 7 days) reduced neointimal hyperplasia by 64.5% (<0.05; intima/media ratio: control, 1.4±0.02; treated, 0.53±0.012) and reduced neointimal c-Kit+ cells. Adenosine inhibits P-SMC migration and proliferation via the A receptor/cyclic AMP/protein kinase A axis, which reduces cyclin D1 expression and activity via inhibiting Akt phosphorylation and Skp2 expression and upregulating p27 levels. Adenosine attenuates neointima formation in part by inhibiting infiltration and proliferation of c-Kit+ P-SMCs.
c-Kit+ 前体细胞平滑肌细胞(P-SMCs)可分化为平滑肌细胞,促进损伤诱导的新生内膜增厚。在这里,我们研究了腺苷是否能减少 P-SMC 的迁移和增殖,以及这是否有助于腺苷抑制新生内膜形成。在人 P-SMCs 中,2-氯腺苷(稳定的腺苷类似物)和 BAY60-6583(A 激动剂)抑制 P-SMC 增殖和迁移。同样,通过用红霉素-9-(2-羟基-3-壬基)腺嘌呤(抑制腺苷脱氨酶)和 5-碘尿苷(抑制腺苷激酶)阻断腺苷代谢来增加内源性腺苷,也减弱了 P-SMC 的增殖和迁移。N-环戊基腺苷(A 激动剂)、CGS21680(A 激动剂)和 N-(3-碘苄基)-腺苷-5'-N-甲基尿苷(A 激动剂)均不影响 P-SMC 的增殖或迁移。2-氯腺苷增加环 AMP,减少 Akt 磷酸化(激活细胞周期蛋白 D 表达),降低细胞周期蛋白 D1 水平(促进细胞周期进程)。此外,2-氯腺苷抑制 Skp2 的表达(促进 p27 的蛋白水解),上调 p27 水平(负性细胞周期调节剂)。受体敲低可防止 2-氯腺苷对环 AMP 产生和 P-SMC 增殖和迁移的影响。同样,抑制腺苷酸环化酶和蛋白激酶 A 可使 P-SMC 免受 2-氯腺苷的抑制作用。在雄性和雌性 P-SMCs 中,腺苷的抑制作用相似。在体内,经皮动脉内(大鼠颈动脉)给予 2-氯腺苷(7 天,20 μmol/L)可使新生内膜增生减少 64.5%(<0.05;内膜/中膜比:对照组,1.4±0.02;治疗组,0.53±0.012),并减少新生内膜 c-Kit+细胞。腺苷通过 A 受体/环 AMP/蛋白激酶 A 轴抑制 P-SMC 的迁移和增殖,通过抑制 Akt 磷酸化和 Skp2 表达,上调 p27 水平,从而减少细胞周期蛋白 D1 的表达和活性。腺苷通过抑制 c-Kit+P-SMC 的浸润和增殖,部分减轻新生内膜的形成。